mesilato de benztropina
sgpharma pvt. ltd.; - mesilato de benztropina - tableta - 2 mg
mesilato de doxazosina
eurofarma laboratorios s.a brasil - mesilato de doxazosina 4,852 mg - comprimidos - cada comprimido contiene: mesilato de doxazosina 4,852 mg equivalente a 4,0 mg de doxazosina base
osimertinib comprimidos recubiertos 40 mg
alembic pharmaceuticals s.p.a. - osimertinib - sin formulas
osimertinib comprimidos recubiertos 80 mg
alembic pharmaceuticals s.p.a. - osimertinib - sin formulas
mesilato de benzatropina
sgpharma pvt. ltd.. - mesilato de benzatropina - inyección iv, im - 2 mg/2 ml
mesilato de fentolamina
sgpharma pvt. ltd; - mesilato de fentolamina - solución para inyección im, iv - 10 mg/ml
mesilato de doxazosina 2 mg
eurofarma laboratorios s.a. brasil - mesilato de doxazosina - incluye 3% de exceso 2,500 mg - comprimido - mesilato de doxazosina - incluye 3% de exceso 2,500 mg/comprimido
tagrisso® 80 mg
astrazeneca ab. - osimertinib (eq. a 95,4 mg de mesilato de osimertinib) - comprimido recubierto - 80 mg
tagrisso® 40 mg
astrazeneca ab. - osimertinib (eq. a 47,7 mg de mesilato de osimertinib) - comprimido recubierto - 40 mg
tagrisso
astrazeneca ab - osimertinib mesilate - carcinoma, pulmón no microcítico - otros agentes antineoplásicos, inhibidores de la proteína quinasa - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.